Dizocilpine-derived K2060 exhibits enhanced blockage at NMDA receptors with impaired Mg2+ block and provides strong protection against audiogenic seizures
Marharyta KolchevaiD, Jakub NetolickýiD, Anna MisiachnaiD, Natalia Rybalko, Petra ZahumenskaiD, Jovana Doderovic, Alena Pakhomova, Claudia Valentina De SanctisiD, Gregory Klein SchneideriD, Katarína HemelíkováiD, Kristyna Rehakova, Štěpán KortusiD, Rostislav TurečekiD, Jan KorábečnýiD, Ondrej Soukup, Marek LadislaviD, Martin HořákiD
Abstract
Background and Purpose: Voltage-dependent Mg2+ block is a defining feature of the GluN1/GluN2 subtype of N-methyl-D-aspartate receptors (NMDARs). We tested how impaired Mg2+ block at GluN1/GluN2A receptors mutated at the GluN2A-N615 position modifies inhibition by dizocilpine-derived K2060 compared with clinically used memantine and ketamine. Experimental Approach: Electrophysiological recordings were performed on recombinant wild-type (WT) and mutated GluN1/GluN2A receptors expressed in HEK293T cells. Acute hippocampal slice electrophysiology and behavioural studies were conducted in WT and knock-in GluN2A-N615S mice. In vivo tolerability and efficacy were evaluated using open field testing, prepulse inhibition (PPI), and protection against audiogenic seizures (AGS). Key Results: Mg2+ reduced the apparent potency of all three blockers and slowed onset at the GluN1/GluN2A-WT receptor. These Mg2+-dependent effects were absent or markedly reduced at the GluN1/GluN2A-N615S and GluN1/GluN2A-N615K receptors. In addition, K2060 showed slower unbinding and greater trapping than memantine. In hippocampal slices from GluN2A-N615S mice, K2060 exhibited enhanced but slower onset inhibition than memantine and ketamine. In vivo, K2060 caused no overt behavioural disruption at 5 mg/kg (i.p.) and did not further disrupt PPI. All three blockers protected GluN2A-N615S mice against AGS at 5 mg/kg (i.p.); only K2060 remained protective at 1 mg/kg (i.p.). Conclusions and Implications: Impaired Mg2+; block removes a physiological constraint on the action of NMDAR blockers. K2060 exhibited the most favourable pharmacological profile, supporting its further evaluation for studies with NMDAR hyperfunction models. Additional pharmacokinetic, safety, and disease-model studies are warranted.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition
Anna Misiachna, Jan Konecny, … Martin Hořák·Biomedicine & PharmacotherapyPeer-reviewed·Jul 24, 2024
- N1 cassette-lacking NMDA receptors mediate the antidepressant activity of ketamine
Alina Tao He, Wenbo Zhang, … Michael W. Salter·bioRxiv·Apr 12, 2025
- State-specific inhibition of NMDA receptors by memantine depends on intracellular calcium and provides insights into NMDAR channel blocker tolerability
Matthew B. Phillips, Nadya V. Povysheva, … Jon W. Johnson·bioRxiv·Apr 1, 2024
- GluN2D-containing NMDA receptors support dentate granule cell excitability, synaptic plasticity, and memory
Coralie Berthoux, Alma Rodenas-Ruano, … Pablo E. Castillo·bioRxiv·Jul 3, 2026
- Mechanisms for zinc and proton inhibition of the GluN1/GluN2A NMDA receptor
F. Jalali-Yazdi, S. Chowdhury, … E. Gouaux·bioRxiv·Jul 26, 2018
- Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor Potentiation
Chad R. Camp, Tue G. Banke, … Stephen F. Traynelis·The Journal of PhysiologyPeer-reviewed·Jun 25, 2025